Necl-5/Tage4/poliovirus receptor/CD155 is the poliovirus receptor and upregulated in rodent and human carcinoma. We have recently shown that mouse Necl-5 is upregulated by an oncogenic Ki-Ras (V12Ki-Ras) in NIH3T3 cells and enhances cell movement induced by growth factors, including platelet-derived growth factor and fibroblast growth factor (FGF), in an integrin a v b 3 -dependent manner in wild type and V12Ki-Ras-transformed NIH3T3 cells. In addition, it enhances the growth factor-induced cell proliferation. We examined here how mouse Necl-5 was upregulated by V12Ki-Ras in NIH3T3 cells. Expression of the luciferase reporter gene fused to the Necl-5 promoter was induced by V12Ki-Ras in NIH3T3 cells. This induction was mediated through the Raf-MEK-ERK pathway. The Necl-5 promoter has an AP-1-binding site and this site was required for the V12Ki-Ras-induced activation of the Necl-5 promoter. Expression of the luciferase reporter gene fused to the Necl-5 promoter was also induced by FGF through the Raf-MEK-ERK-AP-1 pathway in NIH3T3 cells. These results indicate that the expression of mouse Necl-5 is induced by FGF or V12Ki-Ras through the Raf-MEK-ERK-AP-1 pathway.
Introduction
Necl-5/Tage4/poliovirus receptor (PVR)/CD155 is an immunoglobulin (Ig)-like molecule having a domain structure consisting of one extracellular region with three Ig-like loops, one transmembrane region, and one cytoplasmic region (Mendelsohn et al., 1989; Koike et al., 1990; Chadeneau et al., 1994 Chadeneau et al., , 1996 . Human PVR/ CD155 was originally identified as the human PVR (Mendelsohn et al., 1989; Koike et al., 1990) , whereas Tage4 was originally identified as the product of a gene overexpressed in rat and mouse colon carcinoma (Chadeneau et al., 1994 (Chadeneau et al., , 1996 . PVR/CD155 has subsequently been shown to be overexpressed in human colorectal carcinoma and malignant glioma (Gromeier et al., 2000; Masson et al., 2001) . This molecule with these nomenclatures is tentatively named nectin-like molecule-5, Necl-5. Nectin-like molecules (Necls) have been named for a group of Ig-like molecules of which domain structures are similar to, but slightly different from, those of nectins . Nectins are Ca 2 þ -independent Ig-like cell-cell adhesion molecules, which constitute a family consisting of four members, nectin-1, -2, -3, and -4 Takai and Nakanishi, 2003) . Nectins form cis-dimers, followed by formation of trans-dimers (trans-interaction), eventually causing cell-cell adhesion. Nectins first form cell-cell adhesion and recruit cadherins to the nectin-based cellcell adhesion sites to form adherens junctions in epithelial cells and fibroblasts. Nectins are associated with the actin cytoskeleton through afadin, a nectin-and actin-filament-binding protein. Although Necls have domain structures similar to those of nectins, they do not directly bind afadin. Necl-5 is one member of the Necl family consisting of five members, Necl-1, -2, -3, -4, and -5. In contrast to nectins, Necl-5 does not show homophilic cell-cell adhesion activity, but heterophilically trans-interacts with nectin-3 and DNAM1 (Bottino et al., 2003; Ikeda et al., 2003; Mueller and Wimmer, 2003) . DNAM1 is an Ig-like molecule having one extracellular region with two Ig-like loops, one transmembrane region, and one cytoplasmic region (Shibuya et al., 1996) . It is specifically expressed in all natural killer cells, T cells, and monocytes. The exact physiological role of this molecule remains unknown, but it laterally associates with lymphocyte function-associated antigen 1 and is implicated in lymphocyte adhesion and signaling (Shibuya et al., 1996 (Shibuya et al., , 2003 .
The role of Necl-5 as PVR has been established, but its physiological role remained unknown for a long time. We have recently found that Necl-5 is functionally associated with integrin a V b 3 at leading edges of migrating wild-type and V12Ki-Ras-transformed NIH3T3 cells (V12Ki-Ras-NIH3T3 cells) and enhances the cell motility induced by growth factors, including platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF), in an integrin a v b 3 -dependent manner . Necl-5 enhances the growth factor-induced activation of Cdc42 and Rac, causing formation of filopodia and lamellipodia, respectively, which eventually enhances cell motility. In addition, we have revealed that Necl-5 enhances the growth factor-induced proliferation of NIH3T3 cells by shortening the period of the G 1 phase of cell cycle . Necl-5 enhances the activation of the Ras-Raf-MEK-ERK signaling and causes upand downregulation of the cell cycle regulators, including cyclins D2 and E, and cyclin-dependent kinase inhibitor p27 Kip1 , in NIH3T3 cells. The physiological role of the heterophilic trans-interaction of Necl-5 with nectin-3 remains unknown, but we have recently shown that it is involved at least partly in cell-cell adhesion at the initial stage (Sato et al., 2004) . Moreover, we have found that Necl-5 is upregulated in V12Ki-Ras-NIH3T3 cells , and that the enhanced motility and proliferation of V12Ki-Ras-NIH3T3 cells are at least partly due to upregulated Necl-5 .
We examined here how mouse Necl-5 was upregulated by FGF or V12Ki-Ras in NIH3T3 cells. Our results indicate that the expression of Necl-5 is induced by FGF or V12Ki-Ras through the Raf-MEK-ERK-AP-1 pathway.
Results

Activation of the Necl-5 promoter by V12Ki-Ras in NIH3T3 cells
We have previously shown that mouse Necl-5 is upregulated by V12Ki-Ras in NIH3T3 cells Kakunaga et al., 2004) . A level of the Necl-5 protein in V12Ki-Ras-NIH3T3 cells increased about eight-fold as compared to that in NIH3T3 cells Kakunaga et al., 2004) . We first examined whether the level of the Necl-5 mRNA is also induced by V12Ki-Ras in NIH3T3 cells. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis revealed that the level of the Necl-5 mRNA in V12Ki-Ras-NIH3T3 cells increased about seven-fold as compared to that in NIH3T3 cells (data not shown). This increase of the Necl-5 mRNA is comparable to the increase of the Necl-5 protein, suggesting that the expression of Necl-5 is regulated by V12Ki-Ras at the transcriptional level.
We next examined whether expression of the luciferase reporter gene fused to the Necl-5 promoter was induced by V12Ki-Ras in NIH3T3 cells. The Necl-5 cDNA recovered by cap trapping revealed the putative transcriptional start site at 56 bp upstream of the translational start codon (Figure 1a) . The 2.5-kb fragment containing the 5 0 -flanking region of the mouse Necl-5 gene was isolated from the mouse genomic DNA. The 2.5-kb fragment (À2400 to þ 57) was cloned into the pGL3-Basic luciferase reporter vector. The resultant reporter construct, pGL3B-2400, was transfected into NIH3T3 cells. In these cells, pGL3B-2400 showed a more than 100-fold higher relative luciferase activity than pGL3-Basic empty vector (data not shown). This result indicates that this fragment contains the promoter activity. We then examined whether expression of the luciferase reporter gene of the pGL3B-2400 construct was induced by V12Ki-Ras. The luciferase activity of the pGL3B-2400 construct was induced by V12Ki-Ras (Figure 1b ). This result indicates that the promoter activity of Necl-5 is stimulated by V12Ki-Ras. To determine which region is responsible for the activation by V12Ki-Ras, the deleted 5 0 -flanking regions, À1000 and À600 to þ 57, were cloned into pGL3-Basic luciferase reporter vector to generate pGL3B-1000 and pGL3B-600, respectively. The luciferase activity of the pGL3B-1000 construct was induced by V12Ki-Ras, but the pGL3B-600 construct was not (Figure 1b) . These results indicate that the regulatory region of Necl-5 responsible for the activation by V12Ki-Ras locates between À1000 and À600 in the Necl-5 promoter. promoter by V12Ki-Ras. NIH3T3 cells were transfected with 100 ng of pGL3B-2400, pGL3B-1000, or pGL3B-600, 10 ng of pRL-TK, and 100 ng of pCMVFc-V12Ki-Ras or pCMVFc. The lysates were assayed for luciferase activities using the luciferase assay system. The results are shown as relative luciferase activity of three different experiments carried out in triplicate (mean7s.d.). The mean value of the cells transfected with pCMVFc was set to 1.0
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Inhibition of the V12Ki-Ras-induced activation of the Necl-5 promoter by a MEK inhibitor
Previous studies indicate that V12Ki-Ras regulates gene expression via various signaling pathways including the Raf-MEK-ERK pathway and the phosphatidylinositol 3-kinase (PI3K) pathway (Mercer, 2000; Sears and Nevins, 2002) . To determine the pathway by which V12Ki-Ras regulates the activity of the Necl-5 promoter, we utilized the inhibitors of MEK and PI3K. V12Ki-Ras-induced activation of the luciferase activity of the pGL3B-1000 construct was blocked by an MEK inhibitor U0126, but not by a PI3K inhibitor LY294002 (Figure 2a and b). These results suggest that the V12Ki-Ras-induced activation of the Necl-5 promoter is mediated through the Raf-MEK-ERK pathway. To confirm this conclusion, we examined the effect of a dominant-active form of MEK (MEK-DA) on the luciferase activity of the pGL3B-1000 construct. The luciferase activity of the pGL3B-1000 construct was activated by MEK-DA ( Figure 2c ). A dominant-active form of MKK6 or MKK7, which activates p38 or JNK MAPK pathways, did not activate the luciferase activity of the pGL3B-1000 construct (data not shown). Taken together, these results indicate that the V12Ki-Rasinduced activation of the Necl-5 promoter is mediated through the Raf-MEK-ERK pathway.
Activation of the Necl-5 promoter by V12Ki-Ras through AP-1
Various transcription factors such as AP-1, Ets, CREB, have been shown to be activated by the Ras-Raf-MEK-ERK pathway (Davis, 1995) . The 1.0-kb region in the Necl-5 promoter, which is responsible for the V12Ki-Rasinduced activation of the Necl-5 promoter, has three putative AP-1-binding sites (À753, À467, and À371) and one Ets binding site (À30). Since the deletion analysis of the Necl-5 promoter revealed that the regulatory region of Necl-5 responsible for the V12Ki-Ras-induced activation of the Necl-5 promoter locates between À1000 and À600, we examined whether the AP-1 site (À753) is required for the V12Ki-Ras-induced activation of the Necl-5 promoter. Mutation in the AP-1 site (À753) abolished the V12Ki-Ras-induced activation of the Necl-5 promoter ( Figure 2d ). Mutations in other AP-1 sites (À467 and À371) did not affect the V12Ki-Ras-induced activation of the Necl-5 promoter (data not shown). Thus, the AP-1 site (À753) is required for the V12Ki-Ras-induced activation of the Necl-5 promoter. To confirm whether AP-1 binds to this AP-1 site (À753) in the Necl-5 promoter, we performed gel shift analysis. The purified AP-1 protein specifically bound to the AP-1 site (À753), but not the mutated AP-1 site (À753) (Figure 3 ). Taken together, these results indicate that the V12Ki-Ras-induced activation of the Necl-5 promoter is mediated by AP-1.
Increase of the Necl-5 mRNA by serum and FGF in NIH3T3 cells
We have previously shown that Necl-5 enhances the cell motility and proliferation induced by serum or growth factors, including PDGF and FGF Kakunaga et al., 2004) . Since the Ras-Raf-MEK-ERK pathway is activated by serum or these growth factors, promoter. NIH3T3 cells were transfected with 100 ng of pGL3B-1000 or pGL3B-1000 (À753DAP-1), 10 ng of pRL-TK, and 100 ng of pCMVFc-V12Ki-Ras or pCMVFc. The lysates were assayed for luciferase activities using the luciferase assay system. The results are expressed as relative luciferase activity of three different experiments carried out in triplicate (mean7s.d.). The mean value of cells transfected with pCMVFc was set to 1.0
Transcriptional activation of Necl-5/Tage4/PVR/CD155 T Hirota et al we next examined whether the expression of Necl-5 is also regulated by serum or these growth factors. We first examined the level of the Necl-5 mRNA during seruminduced proliferation in NIH3T3 cells (Figure 4 ). NIH3T3 cells were starved of serum for 24 h and then cultured in the presence of serum. The levels of the Necl-5 mRNA was increased in first 2 h after the serum stimulation (Figure 4 ). We also examined whether the levels of the Necl-5 mRNA was increased by various growth factors, PDGF, FGF, epidermal growth factor (EGF), and insulin. The levels of the Necl-5 mRNA was increased by FGF and PDGF, but not by EGF or insulin (Figure 4) .
Activation of the Necl-5 promoter by serum and FGF through the Raf-MEK-ERK-AP-1 pathway
We next examined whether the promoter activity of Necl-5 is stimulated by serum and FGF. Expression of the luciferase reporter gene fused to the Necl-5 promoter, pGL3B-2400, was induced by serum and FGF (Figure 5a and b) . To examine whether the serumor FGF-induced activation of the Necl-5 promoter was also mediated by the Raf-MEK-ERK pathway, we examined the effect of the MEK inhibitor. The serumand FGF-induced activation of the luciferase activity of pGL3B-2400 was blocked by the MEK inhibitor ( Figure  5a and b). These results suggest that the serum-and FGF-induced activation of the Necl-5 promoter is also mediated through the Raf-MEK-ERK pathway. Finally, we examined whether the serum-or FGF-induced activation of the Necl-5 promoter was also mediated by AP-1. Mutation in the AP-1 site (À753) abolished the serum-and FGF-induced activation of the luciferase activity of pGL3B-2400 ( Figure 6 ). Thus, the same AP-1 site is also required for the serum-and FGF-induced activation of the Necl-5 promoter. Taken together, the serum-and FGF-induced activation of the Necl-5 promoter is mediated by the Raf-MEK-ERK-AP-1 pathway.
Discussion
Although mouse Necl-5 has been reported to be upregulated in V12Ki-Ras-NIH3T3 cells , it remains unknown how mouse Necl-5 is upregulated. In the present study, we have first shown that the expression of Necl-5 is mainly regulated at the transcriptional levels; the levels of the Necl-5 mRNA and the promoter activity of Necl-5 are stimulated by V12Ki-Ras. We have then shown here that the V12Ki-Ras-induced activation of the Necl-5 promoter is mediated through the Raf-MEK-ERK-AP-1 pathway; the V12Ki-Ras-induced activation of the Necl-5 promoter is blocked by an MEK inhibitor; the promoter activity of Necl-5 is activated by MEK-DA; and the AP-1-binding site (À753) in the Necl-5 promoter is responsible for the V12Ki-Ras-induced activation of the Necl-5 promoter. It has been reported that the expression of human Necl-5 is regulated by various transcription factors including AP-2, nuclear respiratory factor (NRF), and sonic hedgehog (Solecki et al., 1999 (Solecki et al., , 2000 (Solecki et al., , 2002 . The 280-bp region of the core promoter of human Necl-5 does not contain a putative AP-1-binding site, and the 1-kb region of the promoter of mouse Necl-5 does not contain a putative AP-2-, NRF-, or sonic Figure 3 Binding of AP-1 with the AP-1-binding site (À753) in the Necl-5 promoter. AP-1 protein (1 mg) was incubated with the 32 Plabeled oligonucleotides of the AP-1-binding site (À753) and the mutated AP-1-binding site of the Necl-5 promoter in the gel shift binding buffer. For the competition experiments, unlabeled oligonucleotides were added, before the AP-1 protein was incubated with the 32 P-labeled oligonucleotides. The samples were then electrophoresed on 4% acrylamide gel with 0.5 M Tris-borate EDTA, and the gels were dried, followed by autoradiography. Wt, the AP-1-binding site (À753); Mut, the mutated AP-1-binding site; competitor, unlabeled competitor; and arrowhead, the DNAprotein complex Figure 4 Increase of the Necl-5 mRNA by serum and FGF. The levels of the Necl-5 mRNA in the serum-and various growth factor-induced cell proliferation. NIH3T3 cells were seeded, starved of serum, and cultured in the presence of 10% serum, 1.1 nM FGF, 4.0 nM PDGF, 16 nM EGF, or 10 mg/ml insulin for 0, 2, or 4 h. Total RNA was isolated. The levels of the Necl-5 mRNA were normalized to that of the GAPDH mRNA in the same samples. The level of the Necl-5 mRNA at 0 h was set to 1.0
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T Hirota et al hedgehog-binding site. Thus, the expression of the human and mouse Necl-5 genes may be differently regulated by different transcription factors. However, since human Necl-5 is upregulated in human colorectal carcinoma and malignant glioma (Gromeier et al., 2000; Masson et al., 2001) , the expression of human Necl-5 may be similarly regulated by oncogenic Ras and the Raf-MEK-ERK-AP-1 pathway through a putative AP-1-binding site outside the core promoter. Alternatively, the expression of human Necl-5 may be regulated by oncogenic Ras through other transcription factors such as Ets and CREB or a pathway different from the Raf-MEK-ERK pathway. It should be elucidated whether human Necl-5 is regulated by AP-1 and whether mouse Necl-5 is regulated by other transcription factors.
We have also shown here that the promoter activity of Necl-5 is activated by serum and FGF through the Raf-MEK-ERK-AP-1 pathway. This is consistent with the observation that serum and FGF activate Ras. We have previously shown that Necl-5 enhances the serum-, PDGF-, or FGF-induced activation of the Ras-Raf-MEK-ERK pathway . Thus, Necl-5 seems to regulate its expression positively through the Ras-Raf-MEK-ERK pathway. Consistently, a dominant-negative mutant of Necl-5 inhibits the serum-induced activation of the Necl-5 promoter (data not shown). Since Necl-5 enhances the serum-and growth factor-induced cell motility and proliferation in an integrin a v b 3 -dependent manner, this positive feedback loop of the expression of Necl-5 is important for the serum-and growth factor-induced cell motility and proliferation. We have previously shown that a dominant-negative mutant of Necl-5 reduces cell motility and proliferation of V12Ki-Ras-NIH3T3 cells Kakunaga et al., 2004) . These effects of the dominant-negative mutant of Necl-5 may be partly dependent on its effect on the promoter activity 
Materials and methods
Construction
The 2.5-kb fragment containing the 5 0 -flanking region of the mouse Necl-5 gene was isolated from the mouse genomic DNA. The following sense primers were used to construct the plasmids, pGL3B-2400, pGL3B-1000, and pGL3B-600; for pGL3B-2400, 5 0 -CTC ACG CGT TCT CAC TAG CTT AGA GAC AAG GGC C-3 0 and 5 0 -CTC CTC GAG GTG GTT CCG GTC CGA TCC AGC TCT TTG TAG-3 0 ; for pGL3B-1000, 5 0 -CTC ACG CGT CAG AAG ACT TGC CCC TCA GAT TCC-3 0 and 5 0 -CTC CTC GAG GTG GTT CCG GTC CGA TCC AGC TCT TTG TAG-3 0 ; and for pGL3B-600, 5 0 -CTC ACG CGT GAG TTC GAG GCC AGC CTT GTC TAC-3 0 and 5 0 -CTC CTC GAG GTG GTT CCG GTC CGA TCC AGC TCT TTG TAG-3 0 . The PCR products were inserted into the MluI-XhoI gap of the pGL3-Basic luciferase reporter vector (Promega). Site-directed mutations of potential AP-1-binding sites (À753, À467, and À371) were introduced into the pGL3B-2400 and pGL3B-1000 plasmids by PCR method. The following primers were used: for pGL3B-2400 (À753DAP-1) and pGL3B-1000 (À753DAP-1), 5 0 -CCC ATA TTC ACA TTA AAA TTC ATA ACA GTA GC-3 0 and 5 0 -GCT ACT GTT ATG AAT TTT AAT GTG AAT ATG GG 3 0 ; for pGL3B-2400 (À467DAP-1) and pGL3B-1000 (À467DAP-1), 5 0 -AAG ATT GAG AAC CAC AAA CCT AGA ATG TGC TTC ATG A-3 0 and 5 0 -TCA TGA AGC ACA TTC TAG GTT TGT GGT TCT CAA TCT T-3 0 ; and for pGL3B-2400 (À371DAP-1) and pGL3B-1000 (À371DAP-1), 5 0 -TAC GGT GGA CCC GGC AAA CAC AGA ACT CAC AGA TCT G-3 0 and 5 0 -CAG ATC TGT GAG TTC TGT GTT TGC CGG GTC CAC CGT A-3 0 .
Cell culture and assays for transfection and reporter gene NIH3T3 cells were obtained from American Type Culture Collection. V12Ras-NIH3T3 cells were prepared as described (Fujioka et al., 1992) . NIH3T3 and V12Ki-Ras-NIH3T3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% calf serum. NIH3T3 cells were seeded at a density of 2.5 Â 10 5 cells per six-well plates for 16 h, and were transfected with 100 ng of pGL3B-2400, pGL3B-1000, or pGL3B-600, 100 ng of V12Ki-Ras expression vector (pCMVFc-V12Ki-Ras), 1.0 mg of MEK-DA expression vector (pSRa-MEK1-DA), or the same amount of an empty vector (pCMVFc or pSRa), and 10 ng of pRL-TK (Promega) as an internal control using the LipofectAMINE PLUS reagent (Invitrogen). After the cells were cultured for 48 h, the cells were harvested in the reporter lysis buffer (Promega), and the lysates were assayed for luciferase activity using the luciferase assay system (Promega). For serum or FGF stimulation, NIH3T3 cells were seeded at a density of 7.5 Â 10 4 cells per six-well plates for 16 h, and were transfected with 200 ng of pGL3B-2400 and 20 ng of pRL-TK as an internal control. After the cells were cultured for 24 h, the cells were starved of serum with DMEM supplemented with 0.5% fatty acid-free BSA for 24 h. After the serum starvation, the quiescent cells were cultured in DMEM containing 10% calf serum or DMEM containing 0.5% fatty acid-free BSA and 1.1 nM FGF-basic (PEPROTECH). The cells were harvested in the reporter lysis buffer (Promega), and the lysates were assayed for luciferase activity, respectively. The MEK inhibitor U0126 and the PI3K inhibitor LY294002 were obtained from Promega.
Determination of the transcription start site
The transcription start site of the mouse Necl-5 transcript was determined using the Cap Site cDNA (NIPPON GENE). Briefly, PCR was performed with Cap Site cDNA RC primer and the antisense primer (5 0 -AGT CAG ACT ACA GTG CAA GGT G-3 0 ) specific to the Necl-5 cDNA using Cap Site cDNA Mouse Liver (NIPPON GENE) as a template. Sequencing analysis of the resultant cloned PCR products indicated the presence of two transcription start sites, 56 and 55 bp upstream of the translational start codon. Since 12 out of 13 cDNAs had the exact sequence containing 56 bp of the Necl-5 promoter, we designated the adenine residue 56 bp upstream of the translational start codon as a major transcription start site.
RNA extraction and RT-PCR
NIH3T3 cells were seeded at a density of 9 Â 10 5 cells per 10 cm dishes. After 4 h, the cells were starved of serum with DMEM supplemented with 0.5% fatty acid-free BSA for 24 h. After the serum starvation, the quiescent cells were cultured in DMEM containing 10% calf serum or DMEM containing 0.5% fatty acid-free BSA and 1.1 nM FGF-b, 4.0 nM PDGF-BB (PEPRO-TECH), 16 nM EGF (Sigma), or 10 mg/ml insulin (Sigma). Total RNAs were isolated from using ISOGEN (NIPPON GENE) and treated with RQ1 RNase-Free DNase (Promega) according to the manufacturer's instructions. The DNase treated total RNAs (0.1 mg each) were used as a template for real time RT-PCR. The oligonucleotide primers used for real time RT-PCR were as follows: for Necl-5, 5 0 -GCC CTC GAA TGT GAA TGG AA-3 0 and 5 0 -GTG GTG CCC GGC TGG-3 0 . The probe used to detect mouse Necl-5 was as follows: 5 0 -FAM-TCA CCG TGA AAT GAA GGA ACC AGG GT-TAMRA-3 0 . The probe and primers of mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were obtained from PE Applied Biosystems. Real time RT-PCR was performed using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) and Taq Man One-Step RT-PCR Master Mix Reagents (PE Applied Biosystems) according to the manufacturer's instructions under the following conditions: reverse transcription at 481C for 30 min, stop of reverse transcription at 951C for 10 min, 40 cycles of denaturation at 951C for 15 s and annealing at 601C for 1 min. Using the external standard curve and the corresponding threshold cycle (C T ) of each sample, the relative concentration of mRNA was calculated using Sequence Detection Software (SDS version 1.7, Applied Biosystems). For each data point, duplicate samples were analysed in parallel, and all assays were repeated with highly reproducible results. The levels of the Necl-5 mRNA were normalized to that of the GAPDH mRNA in the same samples. All results shown in this report represent the averages of these three measurements.
Electrophoretic mobility shift assay TTA TGA ATT TTA ATG TGA-3 0 . These double-stranded oligonucleotides were end-labeled with 32 P-a-ATP using Klenow enzyme (Takara). Electrophoretic mobility shift assay was performed essentially using Gel Shift Assay Systems (Promega). Briefly, the purified AP-1 protein was incubated with 32 P-labeled oligonucleotides in gel shift binding buffer (Promega) for 20 min at room temperature. For the competition experiments, unlabeled oligonucleotides were added 10 min before the purified AP-1 protein was incubated with 32 P-labeled oligonucleotides. The samples were then electrophoresed on 4% acrylamide gel with 0.5 M Tris-borate EDTA, and the gels were dried, followed by autoradiography.
Abbreviations DMEM, Dulbecco's modified Eagle's medium; EGF, epidermal growth factor; FGF, fibroblast growth factor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Ig, immunoglobulin; MEK-DA, a dominant-active form of MEK; Necl, nectin-like molecule; NRF, nuclear respiratory factor; PCR, polymerase chain reaction; PDGF, platelet-derived growth factor; PI3K, phosphatidylinositol 3-kinase; PVR, poliovirus receptor; RT-PCR, reverse transcriptase-polymerase chain reaction; and V12Ki-Ras-NIH3T3 cells, V12Ki-Ras-transformed NIH3T3 cells.
